SCHEMBL2177653

SCHEMBL2177653

CC[CH]c1cccc2c1Cc1ccccc1-2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 1/20 0.51
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
HTR7 P34969 1/20 0.39
HTR2B P41595 1/20 0.39
DRD2 P14416 1/20 0.38
DRD4 P21917 1/20 0.38
DRD3 P35462 1/20 0.38
PGR P06401 1/20 0.37
MAOA P21397 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA4 P22748 1/20 0.36
CA6 P23280 1/20 0.36
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 3/20 0.36
MAPT P10636 2/20 0.36
MIF P14174 2/20 0.36
GAA P10253 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL499695 0.88 PNMT (0.47) PNMTNPC1RAB9AHTR7HTR2B
SCHEMBL23777720 0.86 PNMT (0.46) PNMTNPC1RAB9AHTR7HTR2B
SCHEMBL8715941 0.85 PNMT (0.45) PNMTNPC1RAB9AHTR7HTR2B
SCHEMBL499896 0.83 PNMT (0.49) PNMTNPC1RAB9AHTR7HTR2B
SCHEMBL6421463 0.82 PNMT (0.52) PNMTNPC1RAB9AHTR7HTR2B
SCHEMBL3952483 0.82 PNMT (0.52) PNMTNPC1RAB9AHTR7HTR2B
SCHEMBL30462691 0.81 PNMT (0.47) PNMTNPC1RAB9AHTR7HTR2B
SCHEMBL19418539 0.81 PNMT (0.47) PNMTNPC1RAB9AHTR7HTR2B
SCHEMBL1245608 0.79 PNMT (0.49) PNMTNPC1RAB9AHTR7HTR2B
SCHEMBL68230 0.79 PNMT (0.49) PNMTNPC1RAB9AHTR7HTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239745-A1 METHOD FOR SYNTHESIZING BILIRUBIN Bilix Co., Ltd. (KR) 2024-07-18 US disclosed
EP-4375280-A1 METHOD FOR SYNTHESIZING BILIRUBIN Bilix Co., Ltd. (KR) 2024-05-29 EP disclosed
EP-4371984-A1 METHOD FOR SYNTHESIZING BILIRUBIN Bilix Co., Ltd. (KR) 2024-05-22 EP disclosed
EP-4371985-A1 METHOD FOR SYNTHESIZING BILIRUBIN Bilix Co., Ltd. (KR) 2024-05-22 EP disclosed
CN-117881673-A Synthesis method of bilirubin 株式会社毕丽斯 2024-04-12 CN disclosed
CN-117836290-A Synthesis method of bilirubin 株式会社毕丽斯 2024-04-05 CN disclosed
CN-117813301-A Synthesis method of bilirubin 株式会社毕丽斯 2024-04-02 CN disclosed
CN-117480235-A Heat treatment oil composition 出光兴产株式会社 2024-01-30 CN disclosed
WO-2023018217-A1 METHOD FOR SYNTHESIZING BILIRUBIN 주식회사 빌릭스 2023-02-16 WO disclosed
WO-2023018215-A1 METHOD FOR SYNTHESIZING BILIRUBIN 주식회사 빌릭스 2023-02-16 WO disclosed
EP-1896483-A2 4-PIPERAZINYLTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-03-12 EP disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
EP-1869051-A1 4-PIPERAZINYLTHIENO Ý2,3-D¨PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2007-12-26 EP disclosed
EP-1866317-A1 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2007-12-19 EP disclosed
EP-1844052-A1 THIENO[2,3-D]PYRIMIDINE COMPOUNDS AS INHIBITORS OF ADP-MEDIATED PLATELETS AGGREGATION Pharmacia & Upjohn Company LLC (US) 2007-10-17 EP disclosed
WO-2006103544-A2 4-PIPERAZINYLTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-10-05 WO disclosed
WO-2006103555-A1 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-10-05 WO disclosed
WO-2006103545-A1 4-PIPERAZINYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-10-05 WO disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed
WO-2006079916-A1 THIENO [2,3-D] PYRIMIDINE COMPOUNDS AS INHIBITORS OF ADP-MEDIATED PLATELETS AGGREGATION PHARMACIA & UPJOHN COMPANY LLC (US) 2006-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239745-A1 METHOD FOR SYNTHESIZING BILIRUBIN CYP7A1, UGT1A3, UGT1A1 PNMT 841/4885NPC1 515/4885RAB9A 3538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.